Compare GEMI & ATRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GEMI | ATRC |
|---|---|---|
| Founded | 2014 | 2000 |
| Country | United States | United States |
| Employees | N/A | 1350 |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | N/A | 2005 |
| Metric | GEMI | ATRC |
|---|---|---|
| Price | $4.09 | $28.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | $10.44 | ★ $51.17 |
| AVG Volume (30 Days) | ★ 1.9M | 508.0K |
| Earning Date | 03-19-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 74.74 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $201,630,000.00 |
| Revenue This Year | $69.77 | $15.17 |
| Revenue Next Year | $47.76 | $12.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 15.40 |
| 52 Week Low | $4.55 | $28.32 |
| 52 Week High | $34.67 | $43.18 |
| Indicator | GEMI | ATRC |
|---|---|---|
| Relative Strength Index (RSI) | 26.33 | 37.42 |
| Support Level | N/A | $28.60 |
| Resistance Level | $9.94 | $38.25 |
| Average True Range (ATR) | 0.66 | 1.10 |
| MACD | -0.31 | 0.23 |
| Stochastic Oscillator | 0.68 | 17.71 |
Gemini Space Station Inc is engaged on unlocking the next era of financial, creative, and personal freedom. It envisions a future where crypto will redesign the global financial system, the internet, and money in a way that provides greater choice, independence, and opportunity for all. As a trusted bridge between the traditional financial system and the emerging crypto economy, It is providing access for individuals and institutions to a decentralized future that is more open, fair, and secure. Its core exchange product has expanded over time to become a comprehensive platform for its users to engage with the crypto economy, including a derivatives exchange, staking services, an over-the-counter (OTC) trading desk, institutional-grade custody, and others.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.